First, in vitro cell assays should be used to inhibit or increase ADAM12 expression to verify whether it plays a regulatory role in ccRCC, and second, we could not identify a direct mechanism by which ADAM12 participated in the development and progression of ccRCC. Here, ADAM12 is linked to nonpapillary renal cell carcinoma.